Доклады Академии наукДоклады Академии наук0869-5652The Russian Academy of Sciences1584210.31857/S0869-56524874455-459Research ArticleInhibition of neutrophil elastase and cathepsin G as a new approach to the treatment of psoriasis: from fundamental biology to development of new target-specific drugsKrasavinM. Y.gar-54@mail.ruGureevM. A.gar-54@mail.ruGarabadzhiuА. V.gar-54@mail.ruPashkinA. Y.gar-54@mail.ruZhukovА. S.gar-54@mail.ruKhairutdinovV. R.gar-54@mail.ruSamtsovA. V.gar-54@mail.ruShvetsV. I.<p>Academician of the Russian Academy of Sciences</p>gar-54@mail.ruSaint-Petersburg State UniversitySt.Petersburg State Technological InstituteThe First Sechenov Moscow State Medical University under Ministry of Health of the Russian FederationS.M. Kirov Military Medical Academy"MIREA-Russian Technological University"Institute of General Pathology and Pathophysiology2708201948744554592508201925082019Copyright © 2019, Russian academy of sciences2019<p class="a"><span lang="EN-US">Psoriasis therapy remains extremely relevant area of modern drug design, due to necessity of adverse reactions reduction, inherent for actual methods of therapy. It has been established that two of serine proteases are key agents in psoriasis development: neutrophil elastase 1 (HNE1) and cathepsin G (CatG). Collected molecular data for presented targets forms the basis of molecular modeling strategy for search and identification of new target-specific inhibitors. The result of work is a group of high-priority small-molecule compounds with double-targeted affinity with ability to suppress pro-psoriatic processes, induced by observed serine proteases in the initial stage of disease.</span></p>Virtual screeningCatGELANECathepsin Gpsoriasismultitarget structuresautoimmune diseasesвиртуальный скринингCatGELANEкатепсин Gпсориазмультитаргетностьаутоиммунные заболевания[Gabay C., Towne J.E. Regulation and Function of Interleukin 36 Cytokines in Homeostasis and Pathological Conditions // J. Leukocyte Biol. 2015. V. 97. № 4. P. 645-652.][Sullivan G.P., Davidovich P.B., Sura-Trueba S., Belotcerkovskaya E., Henry C.M., Clancy D.M., Zinoveva A., Mametnabiev T., Garabadzhiu A.V., Martin S.J. Identification of Small-Molecule Elastase Inhibitors as Antagonists of IL 36 Cytokine Activation // FEBS Open Bio. 2018. V. 8. № 5. P. 751-763.][Nero T.L., Parker M.W., Morton C.J. Protein Structure and Computational Drug Discovery // Biochem. Soc. Trans. 2018. V. 46. № 5. P. 1367-1379.][Clancy D.M., Sullivan G.P., Moran H.B.T., Henry C.M., Reeves E.P., McElvaney N.G., Lavelle E.C., Martin S.J. Extracellular Neutrophil Proteases Are Efficient Re-gulators of IL 1, IL 33, and IL 36 Cytokine Activity but Poor Effectors of Microbial Killing // Cell. Repts. 2018. V. 22. № 11. P. 2937-2950.][Henry C.M., Sullivan G.P., Clancy D.M., Afonina I.S., Kulms D., Martin S.J. Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL 36 Family Cytokines // Cell. Repts. 2016. V. 14. № 4. P. 708-722.][Dietrich D., Gabay C. Inflammation: IL 36 Has Proinflammatory Effects in Skin But Not in Joints // Nature Revs. Rheumatol. 2014. V. 10. № 11. P. 639-640.][D’Erme A.M., Wilsmann-Theis D., Wagenpfeil J., Holzel M., Ferring-Schmitt S., Sternberg S., Wittmann M., Peters B., Bosio A., Bieber T., Wenzel J. IL 36gamma (IL 1F9) Is a Biomarker for Psoriasis Skin Lesions // J. Investigative Dermatology. 2015. V. 135. № 4. P. 1025-1032.][Tabeshpour J., Sahebkar A., Zirak M.R., Zeinali M., Hashemzaei M., Rakhshani S., Rakhshani S. Computer-Aided Drug Design and Drug Pharmacokinetic Prediction: A Mini-Review // Current Pharmaceutical Design. 2018. V. 24. № 26. P. 3014-3019.][Hooshdaran B., Kolpakov M.A., Guo X., Miller S.A., Wang T., Tilley D.G., Rafiq K., Sabri A. Dual Inhibition of Cathepsin G and Chymase Reduces Myocyte Death and Improves Cardiac Remodeling after Myocardial Ischemia Reperfusion Injury // Basic Res. Cardiol. 2017. V. 112. № 6. P. 62.][McLoed A.G., Sherrill T.P., Cheng D.S., Han W., Saxon J.A., Gleaves L.A., Wu P., Polosukhin V.V., Karin M., Yull F.E., Stathopoulos G.T., Georgoulias V., Zaynagetdinov R., Blackwell T.S. Neutrophil-Derived IL 1beta Impairs the Efficacy of NF kappaB Inhibitors against Lung Cancer // Cell Repts. 2016. V. 16. № 1. P. 120-132.][Repasky M.P., Shelley M., Friesner R.A. Flexible Ligand Docking with Glide // Current Protocols in Bioinformatics. 2007. V. 8. P. 8-12.][Nussbaum F., Karthaus D., Anlauf S., Klein M., Li V.M.-J., Meibom D., Lustig K., Schamberger J. PCT Int. Appl. WO2009080199 // Chem. Abstr. 2009. V. 151. P. 101-192.][Ilyin A., Kysil V., Krasavin M., Kurashvili I., Ivach-tchenko A.V. Complexity-Enhancing Acid-Promoted Rearrangement of Tricyclic Products of Tandem Ugi 4CC/Intramolecular Diels-Alder Reaction // J. Org. Chem. 2006. V. 71. № 25. P. 9544-9547.][Baell J.B., Holloway G.A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays // J. Med. Chem. 2010. V. 53. № 7. P. 2719-2740.][Verdonk M.L., Berdini V., Hartshorn M.J., Mooij W.T., Murray C.W., Taylor R.D., Watson P. Virtual Screening Using Protein-Ligand Docking: Avoiding Artificial Enrichment // J. Chem. Inform. and Computer Sci. 2004. V. 44. № 3. P. 793-806.]